Absenteeism among employees treated for depression.

Area of Science:

• Occupational Health
• Psychiatry
• Health Economics

Background:

• Depression incurs substantial indirect costs for businesses, primarily through employee absenteeism.
• Understanding the economic impact of depression treatment is crucial for employers and healthcare providers.

Purpose of the Study:

• To evaluate the effect of antidepressant therapy on absenteeism in workers diagnosed with depression.
• To compare the impact of different antidepressant classes on reducing work absence.

Main Methods:

• A study involving 630 workers diagnosed and treated for depression.
• Monthly absenteeism data collected for 6 months pre- and post-antidepressant initiation.
• Comparison of mean absenteeism using pairwise t-tests across different antidepressant cohorts (tricyclic antidepressants and selective serotonin reuptake inhibitors like fluoxetine, sertraline, paroxetine).

Main Results:

• Absenteeism increased prior to antidepressant initiation and decreased following treatment commencement across all groups.
• Selective serotonin reuptake inhibitor cohorts demonstrated similar absenteeism reduction rates for the initial 4 months.
• The paroxetine cohort exhibited higher absenteeism rates in months 5 and 6 post-treatment initiation compared to other SSRIs.

Conclusions:

• Antidepressant treatment is associated with a reduction in depression-related employee absenteeism.
• Different antidepressant medications may have varying effects on indirect economic costs associated with depression.
• Further research is needed to explore the differential impact of various depression treatments on workplace productivity and costs.